Natera Inc Stock Price, News & Analysis

Personalis (Nasdaq: PSNL) and Natera (Nasdaq: NTRA) have launched a partnership to advance personalized oncology. Their collaboration combines Personalis’ NeXT tumor profiling with Natera’s Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease. Natera will validate Signatera assays using Personalis' data and handle commercialization. This non-exclusive agreement aims to enhance the integration of these technologies in clinical and research applications, expanding patient access to innovative cancer monitoring solutions.

Natera, Inc. (Nasdaq: NTRA) and Personalis, Inc. (Nasdaq: PSNL) have announced a partnership aimed at enhancing personalized oncology. This non-exclusive agreement integrates Personalis' NeXT tumor profiling products with Natera's Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease (MRD). Natera will validate Signatera assays using tumor and normal exome data from Personalis and take charge of commercialization. The collaboration aims to improve availability and reliability of advanced cancer diagnostics.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, announced participation in two significant conferences. Alexey Aleshin, MD, will join a panel at the BTIG Virtual MedTech Conference on February 18, 2021, at 10:00 a.m. PT. Additionally, Steve Chapman, CEO, and Mike Brophy, CFO, will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 11:20 a.m. PT. Live webcasts will be available at investor.natera.com.

Natera, Inc. (NASDAQ: NTRA) presented promising results from its SMART study at the SMFM 41st Annual Pregnancy Meeting. This study, the largest of its kind in non-invasive prenatal testing (NIPT), confirmed the market-leading accuracy of Natera's Panorama test. Key findings include 99% sensitivity and over 99.95% specificity for trisomy 21, along with enhanced performance from the new Panorama AI algorithm, which reduced the no-call rate to 1.5%. The study’s results further solidify Panorama's status as the most extensively researched NIPT available.

Natera, Inc. (NASDAQ: NTRA) presented results from its SMART study at the SMFM 41st Annual Pregnancy Meeting. This study, the largest prospective NIPT study with 20,927 participants, validated a new AI-based algorithm for its Panorama test. Key findings revealed a prevalence of 22q11.2 microdeletion at 1/1,524, higher than trisomy 21 and other conditions. Panorama demonstrated the highest sensitivity for common microdeletions and identified small deletions comprising 41% of disease load. Natera aims to promote routine screening for 22q11.2 deletions based on these outcomes.

Natera, Inc. (NASDAQ: NTRA) filed a patent infringement lawsuit against Inivata, Ltd. for allegedly infringing on its U.S. Patent Nos. 10,262,755 and 10,597,709, which cover personalized monitoring and molecular residual disease (MRD) testing in oncology. The lawsuit seeks injunctive relief and monetary damages, as Natera claims Inivata uses its patented technology in oncology products. Natera emphasizes its leadership in tumor-informed MRD testing and its extensive intellectual property portfolio of over 260 assets in the field.

Natera, Inc. (NTRA) announced the presentation of new data on its Prospera test at the American Society of Transplant Surgeons (ASTS) 21st Annual Winter Symposium from January 14-16, 2021. The company will showcase five posters demonstrating how the Prospera test can detect kidney transplant rejection. Highlights include a study showing 56.2% of patients with delayed graft function had elevated donor-derived cfDNA levels, and a separate analysis indicating a 64.3% active rejection rate among kidney transplant recipients with positive results from the Prospera test.

Natera (NASDAQ: NTRA) announced the presentation of new findings on its Signatera test at the 2021 ASCO GI Symposium from January 15-17, 2021. This includes an oral presentation by Tenna V. Henriksen on January 16, highlighting a multi-center study of 265 colorectal cancer patients that indicates early detection of recurrence 8 months prior to traditional methods. A poster presentation will also feature a study of 122 stage II-III patients, showing a correlation between minimal residual disease (MRD) status and relapse rates.

Natera, a leader in cell-free DNA testing, will webcast a live presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. PT. CEO Steve Chapman and CFO Mike Brophy will discuss the company's recent business activities and provide an overview, followed by a Q&A session. Investors can access the live presentation and archived content on investor.natera.com. Natera aims to transform disease management worldwide, focusing on women's health, oncology, and organ health.